Clinical Trials Using Duvelisib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Duvelisib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL).
Location: 14 locations
Duvelisib and Romidepsin or Bortezomib in Treating Patients with Relapsed or Refractory T-cell Lymphoma
This phase I trial studies the side effects and best dose of duvelisib when given together with romidepsin or bortezomib in treating patients with T-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Duvelisib, romidepsin, and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Location: 10 locations
FORRDuvelisib and Venetoclax in Treating Patients with Richter's Syndrome or Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase I / II trial studies the side effects and best dose of venetoclax when given together with duvelisib and to see how well they work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or does not respond to treatment, or Richter's syndrome. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax targets a protein called BCL-2, which helps cancer cells survive. Combining duvelisib and venetoclax may be able to prevent tumor from growing.
Location: 7 locations
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
This study will assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in subjects with recurrent or metastatic (R / M) head and neck squamous cell carcinoma (HNSCC).
Location: 4 locations
Duvelisib and Nivolumab in Treating Patients with Richter Syndrome or Transformed Follicular Lymphoma
This phase I trial studies the side effects and best dose of duvelisib when given together with nivolumab in treating patients with Richter syndrome or transformed follicular lymphoma. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving duvelisib and nivolumab may work better in treating patients with Richter syndrome or transformed follicular lymphoma compared to giving duvelisib or nivolumab alone.
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL / SLL Previously Enrolled in Study IPI-145-07
A Phase 3 (extension) clinical trial to examine the efficacy of IPI-145 monotherapy or ofatumumab monotherapy in subjects with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who experienced disease progression after treatment with IPI-145 or Ofatumumab in Study IPI-145-07.
Location: Dana-Farber Cancer Institute, Boston, Massachusetts
Duvelisib Maintenance after Autologous Stem Cell Transplant for the Treatment of T-Cell or Indolent B-Cell Lymphoma
This phase II trial studies how well duvelisib works as maintenance therapy after autologous stem cell transplant works in treating patients with T-cell or indolent B-cell lymphomas. Maintenance therapy refers to treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Treatment with duvelisib may help keep lymphoma in remission after transplant.
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Intermittent Duvelisib Dosing in Treating Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies how well duvelisib on an intermittent (irregular) dosing schedule works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving duvelisib on an intermittent schedule may result in similar effectiveness with less amount of severe side effects.
Location: 2 locations
Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL / SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.
Location: See Clinical Trials.gov
Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma
This pilot trial studies the side effects and feasibility of microdevice for in situ candidate drug screening in skin lesions of T-cell lymphoma. Implanting and retrieving a microdevice that releases up to 19 drugs directly within a skin lesion may be a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma or peripheral T cell lymphoma.
Location: 2 locations
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL / SLL and FL
This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.
Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin